  Assessing response to therapy in lymphoma is important for determining patients ' prognosis , guiding subsequent treatment , and may be used as an outcome measure of prognostic and therapeutic trials. Traditionally , computed tomography was the mainstay for response assessment and was predominantly performed at the end of treatment , whereas the most recent guidelines propose